FOLOTYN PRALATREXATE 普拉曲沙

Pralatrexate is an antifolate and a dihydrofolate reductase inhibitor, mainly used to treat peripheral T-cell lymphoma (PTCL). Its mechanism of action is to interfere with cancer cell folate metabolism, block DNA synthesis, and inhibit tumor proliferation. ‌
Indications
Pralatrexate is suitable for relapsed or refractory peripheral T-cell lymphoma, especially for patients who are ineffective with traditional therapies. Clinical studies have shown that its overall response rate for cutaneous T-cell lymphoma is 100%, and the complete response rate is 67%. ‌
Dosage and Administration
The recommended dose for adults is 30 mg/m² intravenously once a week for 7 consecutive weeks (6 weeks in total). Patients with renal insufficiency need to adjust the dose to 15 mg/m². Vitamin B12 and folic acid need to be supplemented before treatment. ‌
Adverse Reactions
Common adverse reactions include bone marrow suppression, oral mucositis, fatigue, and nausea. Regular monitoring of blood routine and adjustment of dose are required to control side effects. ‌
1